Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Nutrition ; 32(9): 995-1001, 2016 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-27130470

RESUMEN

OBJECTIVE: To investigate the effects of glycyrrhizic acid supplementation on glucose and lipid metabolism in rodents consuming a high-fat, high-sucrose diet. METHODS: Twenty-four male, 8-week old Sprague Dawley rats with an initial weight of 160 to 200 g were randomised into three groups (n = 6 for each group): groups A (standard rat chow), B (high-fat, high-sucrose diet), and C (high-fat, high-sucrose diet + 100 mg/kg/d of glycyrrhizic acid via oral administration). The rats were treated accordingly for 4 wk. Glycaemic parameters, lipid profile, stress hormones, and adiponectin levels were measured after the treatment. Relative gene expressions of peroxisome proliferator-activated receptor α and γ, lipoprotein lipase as well as gluconeogenic enzymatic activities in different tissues were also determined. RESULTS: Consumption of high-fat, high-sucrose diet triggered hyperglycaemia, insulin resistance, and dyslipidemia, which were effectively attenuated by supplementation with glycyrrhizic acid. Glycyrrhizic acid supplementation also effectively reduced circulating adrenaline, alleviated gluconeogenic enzymes overactivity, and promoted the upregulation of lipoprotein lipase expression in the cardiomyocytes and skeletal muscles. A high calorie diet also triggered hypoadiponectinaemia and suppression of peroxisome proliferator-activated receptor γ expression, which did not improve with glycyrrhizic acid treatment. CONCLUSION: Supplementation with glycyrrhizic acid could alleviate high calorie diet-induced glucose and lipid metabolic dysregulations by reducing circulatory stress hormones, normalizing gluconeogenic enzyme activities, and elevating muscular lipid uptake. The beneficial effects of these bioactivities outweighed the adverse effects caused by diet-induced repression of peroxisome proliferator-activated receptor γ expression, resulting in the maintenance of lipid and glucose homeostasis.


Asunto(s)
Antiinflamatorios/farmacología , Dieta Alta en Grasa/efectos adversos , Ácido Glicirrínico/farmacología , Síndrome Metabólico/prevención & control , PPAR gamma/antagonistas & inhibidores , Sacarosa/administración & dosificación , Adiponectina/sangre , Animales , Antiinflamatorios/sangre , Grasas de la Dieta/administración & dosificación , Epinefrina/sangre , Gluconeogénesis/efectos de los fármacos , Ácido Glicirrínico/sangre , Lipoproteína Lipasa/sangre , Lipoproteína Lipasa/efectos de los fármacos , Masculino , Síndrome Metabólico/sangre , PPAR gamma/sangre , Ratas , Ratas Sprague-Dawley
2.
Nutrients ; 6(11): 4856-71, 2014 Nov 04.
Artículo en Inglés | MEDLINE | ID: mdl-25375630

RESUMEN

Glycyrrhizic acid (GA) ameliorates many components of the metabolic syndrome, but its potential therapeutic use is marred by edema caused by inhibition of renal 11ß-hydroxysteroid dehydrogenase 2 (11ß-HSD2). We assessed whether 100 mg/kg per day GA administered orally could promote metabolic benefits without causing edema in rats fed on a high-sucrose diet. Groups of eight male rats were fed on one of three diets for 28 days: normal diet, a high-sucrose diet, or a high-sucrose diet supplemented with GA. Rats were then culled and renal 11ß-HSD2 activity, as well as serum sodium, potassium, angiotensin II and leptin levels were determined. Histological analyses were performed to assess changes in adipocyte size in visceral and subcutaneous depots, as well as hepatic and renal tissue morphology. This dosing paradigm of GA attenuated the increases in serum leptin levels and visceral, but not subcutaneous adipocyte size caused by the high-sucrose diet. Although GA decreased renal 11ß-HSD2 activity, it did not affect serum electrolyte or angiotensin II levels, indicating no onset of edema. Furthermore, there were no apparent morphological changes in the liver or kidney, indicating no toxicity. In conclusion, it is possible to reap metabolic benefits of GA without edema using the current dosage and treatment time.


Asunto(s)
Sacarosa en la Dieta/administración & dosificación , Edema/inducido químicamente , Ácido Glicirrínico/farmacología , 11-beta-Hidroxiesteroide Deshidrogenasa de Tipo 2/antagonistas & inhibidores , 11-beta-Hidroxiesteroide Deshidrogenasa de Tipo 2/metabolismo , Administración Oral , Angiotensina II/sangre , Animales , Sacarosa en la Dieta/efectos adversos , Riñón/efectos de los fármacos , Riñón/enzimología , Leptina/sangre , Hígado/efectos de los fármacos , Hígado/metabolismo , Masculino , Síndrome Metabólico/tratamiento farmacológico , Potasio/sangre , Ratas , Ratas Sprague-Dawley , Sodio/sangre
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA